Mark Talamonti to Pharmacogenomic Testing
This is a "connection" page, showing publications Mark Talamonti has written about Pharmacogenomic Testing.
Connection Strength
0.040
-
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. J Eur Acad Dermatol Venereol. 2020 Jan; 34(1):112-118.
Score: 0.040